Covishield (Oxford/AZ formulation) - versus control - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

safety endpoints 00

adverse events 1.31 [0.98, 1.76]< 10%1 study (1/-)3.4 %NAnot evaluable non important-
intracranial hemorrhage 0.25 [0.00, 12.61]< 10%1 study (1/-)75.2 %NAnot evaluable non important-
ischemic stroke 0.25 [0.00, 12.61]< 10%1 study (1/-)75.2 %NAnot evaluable non important-
Myocardial infarction 0.25 [0.00, 12.61]< 10%1 study (1/-)75.2 %NAnot evaluable non important-
pulmonary embolism 0.25 [0.00, 12.61]< 10%1 study (1/-)75.2 %NAnot evaluable non important-
serious adverse events (SAE), any 1.89 [0.43, 8.29]< 10%1 study (1/-)20.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.